These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15813666)

  • 1. Lucinactant: in neonatal respiratory distress syndrome.
    Moen MD; Perry CM; Wellington K
    Treat Respir Med; 2005; 4(2):139-45; discussion 146-7. PubMed ID: 15813666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
    Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.
    Dechant KL; Faulds D
    Drugs; 1991 Nov; 42(5):877-94. PubMed ID: 1723378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
    Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
    Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous surfactant use in neonates.
    Ishisaka DY
    Ann Pharmacother; 1996 Apr; 30(4):389-98. PubMed ID: 8729894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Jul; (3):CD006069. PubMed ID: 17636826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD006069. PubMed ID: 17943881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lucinactant for the prevention of respiratory distress syndrome in premature infants.
    Jordan BK; Donn SM
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):115-21. PubMed ID: 23473590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome.
    Gastiasoro-Cuesta E; Alvarez-Diaz FJ; Rey-Santano C; Arnaiz-Renedo A; Loureiro-Gonzalez B; Valls-i-Soler A
    Pediatrics; 2006 Feb; 117(2):295-303. PubMed ID: 16452346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
    Hudak ML; Martin DJ; Egan EA; Matteson EJ; Cummings NJ; Jung AL; Kimberlin LV; Auten RL; Rosenberg AA; Asselin JM; Belcastro MR; Donohue PK; Hamm CR; Jansen RD; Brody AS; Riddlesberger MM; Montgomery P
    Pediatrics; 1997 Jul; 100(1):39-50. PubMed ID: 9200358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surfactant respiratory therapy using Surfaxin/sinapultide.
    Lal MK; Sinha SK
    Ther Adv Respir Dis; 2008 Oct; 2(5):339-44. PubMed ID: 19124381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calfactant: a review of its use in neonatal respiratory distress syndrome.
    Onrust SV; Dooley M; Goa KL
    Paediatr Drugs; 1999; 1(3):219-43. PubMed ID: 10937453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. The American Exosurf Neonatal Study Group I.
    Stevenson D; Walther F; Long W; Sell M; Pauly T; Gong A; Easa D; Pramanik A; LeBlanc M; Anday E
    J Pediatr; 1992 Feb; 120(2 Pt 2):S3-12. PubMed ID: 1735849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
    Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS.
    Wolfson MR; Wu J; Hubert TL; Gregory TJ; Mazela J; Shaffer TH
    Pediatr Res; 2012 Oct; 72(4):375-83. PubMed ID: 22821059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.
    Pediatrics; 1996 Jan; 97(1):1-6. PubMed ID: 8545199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary distribution of lucinactant and poractant alfa and their peridosing hemodynamic effects in a preterm lamb model of respiratory distress syndrome.
    Terry MH; Merritt TA; Harding B; Schroeder H; Merrill-Henry J; Mazela J; Gregory TJ; Segal R; Power GG; Blood AB
    Pediatr Res; 2010 Sep; 68(3):193-8. PubMed ID: 20531255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.